News

Two posters presented at MS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.

The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

The chief medical officer at Cure SMA spoke to the ongoing work that the organization does in advocating for patients with spinal muscular atrophy, particularly for newborn screening.

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

The director of the VA Southwest Parkinson’s Disease Research, Education and Clinical Centers discussed how loneliness can impact Parkinson disease severity and how holistic approaches to care may help.

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.

The COMT inhibitor, which was approved in April 2020, may be a worthwhile option as a first-line adjunctive treatment for those with Parkinson disease with motor fluctuations.

Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.

Day of Dravet, a 1-day virtual event on Saturday, October 17th will give attendees an opportunity to meet industry representatives and ask questions.

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, discuss their experience with EpiTRAQ and the role it can play in optimizing the epilepsy care transition.

The new center is part of the first cohort of centers nationally to receive this new NIH funding and is the first and only in Nevada.

The 7th International LGS Foundation Family Conference features interactive Q&A's, breakout sessions, interactive games, and access to the after party with LGS caregivers.

Register now to participate in the Dravet Syndrome Foundation's Virtual Steps Toward a cure beginning September 19th.

Supporting patient activation of their knowledge, skill, and confidence in managing their health may empower patients in times of stress.

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

Scores reflective of tremor in each body part and task performance improved by 71% in patients from baseline before first thalamotomy to 6 months after second thalamotomy.

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

Neurology News Network for the week ending September 12, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Mind Moments, a podcast from NeurologyLive, brings you an exclusive interview with Stewart Tepper, MD, in part 1 of this special 3-part multimedia series on the evolution of migraine care.

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.